Congenital myotonic dystrophy (CDM) is a life-limiting genetic disorder present at birth, marked by profound motor and cognitive impairments. CDM is the most severe form of myotonic dystrophy type 1 (DM1), both caused by a cytosine–thymine–guanine (CTG) repeat expansion in the DM1 protein kinase gene. Clinical trials targeting the shared disease mechanism in DM1 adults have shown promise. However, a lack of validated clinical end points in early childhood and a limited understanding of the variable disease progression are challenges to trial design in CDM. This longitudinal cohort study identifies predictors of motor function in children with CDM to inform future clinical trials.
Kiefer et al. (Wed,) studied this question.